A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Recruiting

Phase 2

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Sponsor:

Corcept Therapeutics

Code:

NCT06108219

Conditions

Nonalcoholic Steatohepatitis (NASH)

Metabolic Dysfunction-associated Steatohepatitis (MASH)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Miricorilant (Cohort A)

Placebo (Cohort A)

Miricorilant (Cohort B)

Placebo (Cohort B)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Corcept Therapeutics on 2024-12-10.